Funding agencies: The study was sponsored by Boehringer-Ingelheim.
Article first published online: 7 MAR 2012
Copyright © 2012 Movement Disorder Society
Volume 27, Issue 6, pages 775–778, May 2012
How to Cite
Kurlan, R., Crespi, G., Coffey, B., Mueller-Vahl, K., Koval, S., Wunderlich, G. and on behalf of the Pramipexole for TS Trial Investigators (2012), A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Mov. Disord., 27: 775–778. doi: 10.1002/mds.24919
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
See Appendix for names of Pramipexole for TS Trial Investigators
- Issue published online: 30 MAY 2012
- Article first published online: 7 MAR 2012
- Manuscript Accepted: 1 JAN 2012
- Manuscript Revised: 9 DEC 2011
- Manuscript Received: 15 JUN 2011
- Tourette's syndrome;
- dopamine agonist;
- treatment, clinical trial
Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome.
There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome.
There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole (−7.16) and placebo (−7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent- and investigator-scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo.
There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder. © 2012 Movement Disorder Society